Located in Rancho Cordova, California, Cesca Therapeutics specializes in the research, development, and commercialization of autologous cell-based therapeutics for regenerative medicine applications. With the stem cell and cord blood marketplace, the company is best known for it automated blood and bone marrow processing systems, such as the AutoXpress® Platform (AXP®), the MarrowXpress® Platform, the BioArchive® System, and others.
Already a dominant player with the cord blood banking markets, Cesca Therapeutics continues its dominance with today’s announcement that the Texas Stem Cell has entered into an agreement to use Cesca’s AutoXpress technology. Located in Houston, Texas Stem Cell is a stem cell bank that offer the storage of cord blood, cord tissue, and placenta. As a “hybrid” bank, it offers both private (fee-based) storage and public (free) donation of stem cell samples.
To learn more about the agreement, see the full press release from Cesca Therapeutics below.
Texas Stem Cell Enters Into an Agreement With Cesca Therapeutics for Use of AutoXpress® Technology for Cord Blood Processing
Source: Cesca Therapeutics Inc. / GlobeNewswire
RANCHO CORDOVA, Calif. and HOUSTON, Feb. 09, 2016 (GLOBE NEWSWIRE) — Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that Texas Stem Cell has committed to utilizing Cesca’s AutoXpress® AXP technology for its cord blood banking business. The AXP platform includes a ‘smart’ processing device and sterile disposable that automatically concentrates the stem cells from a cord blood unit in less than one hour and delivers them directly into Cesca’s patented sample bag which is optimized for cryopreservation and storage. Cesca’s AXP technology is widely used in cord blood banks around the world and has been referenced in dozens of clinical publications. Recently, clinical focus on cord blood has expanded due to the emergence of protocols enabling the expansion of cord blood cells in vitro, for subsequent therapeutic use in treatments for many forms of blood cancers including leukemia and lymphomas.
Texas Stem Cell (TSC) is the first Hybrid cord blood and tissue and placenta bank in Texas. Based in Houston, TSC is located in close proximity to the largest medical center in the world. TSC is dedicated to the processing and preservation of stem cells from a newborn’s cord blood, cord tissue, placenta and adipose tissue for future use in regenerative medicine. According to Dr. Michael Allon, a medical advisor to Texas Stem Cell, the decision to adopt the AXP technology was primarily based on performance, notably the system’s superior cell recovery and speed compared to the competition. TSC also employs the most advanced technology and proprietary non-enzymatic methods available for isolating mesenchymal stem cells (MSC) and endothelial progenitor cells (EPC) from cord tissue as well as preserving cells in a CGMP-compliant facility. Their patented method of transporting cord blood and cord tissue provides one of the most effective temperature maintenance methods, optimizing both stem cell viability and potency, and positioning TSC as a pioneer in the industry. “The bank anticipates scheduling cord blood and tissue collection and storage for clients beginning in Spring, 2016,” commented Lisa Benjamini, Texas Stem Cell’s CEO. “We have acquired the best technologies available for our process in order to offer superior services to our clients,” she added.
About Cesca Therapeutics Inc.
Cesca Therapeutics Inc. (www.cescatherapeutics.com) is engaged in the research, development and commercialization of autologous cell-based therapeutics for use in regenerative medicine. The Company is a leader in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. These include:
- SurgWerks™: proprietary stem cell therapy point-of-care kits for the treatment of vascular and orthopedic indications that integrate the following indication specific elements:
- Cell harvesting
- Cell processing and selection
- Cell diagnostics
- Cell delivery
- CellWerksTM: an integrated system which includes a protocol, disposables and equipment for intra-laboratory use in treatment of oncological and hematological disorders.
- The AutoXpress® (AXP): a proprietary automated device, along with companion sterile blood processing disposables, for the harvesting of stem cells from cord blood.
- The MarrowXpress™ (MXP): a device and disposable system based on the AutoXpress platform for the isolation and concentration of stem cells from bone marrow. Self-powered and microprocessor-controlled, the MXP contains flow control and optical sensors and concentrates white blood cells from bone marrow to a user-defined volume in 40 minutes while retaining over 90% of mononuclear cells (MNCs).
- The BioArchive® System: an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries, for cryopreservation and archiving of cord blood stem cell units for transplant.
About Texas Stem Cell
Texas Stem Cell (TSC), located in Houston, Texas, is the first Hybrid cord blood, tissue, and placenta bank in Texas and is dedicated to preserving stem cells from a newborn’s cord blood, cord tissue, and placenta for both family banking as well as public cord blood banking. Their team with over 150 years of experience makes them leaders in the field. Their state of the art CGMP-compliant facility utilizes the most advanced technology and equipment for isolation and storage of cells from a variety of sources. As leaders in regenerative medicine our quest for excellence lies in our collaboration with world experts and knowledge base from physicians in different fields including infertility, obstetrics, endocrinology immunology, and oncology.
For more information contact us at: 1-844-Tex-Cell or visit us on-line at www.TexasStemCell.com.
Forward Looking Statements
The statements contained herein may include statements of future expectations and other forward looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements, including our ability to initiate and prosecute the pivotal CLIRST III trial, our ability to obtain efficacy consistent with prior CLI studies, continued FDA approval, Medicare reimbursement approval, timing of the Company’s future submission of IDE, PMA and/or Medicare reimbursement applications, or amendments to such applications, and outcomes from such submissions. Further, clinical trial outcomes are not predictable, and results may vary from the Company’s expectations, including the start of any such clinical trials, patient follow up issues, and costs associated with such trials. Further description of other risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics’ forward looking statements is set forth under the caption “Risk Factors” in Cesca Therapeutics’ annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward looking statements. Cesca may, at its discretion, choose to publish on-going interim notifications, requests for further information as received from the FDA, Medicare or equivalent foreign agencies, but as a general policy only makes announcements regarding material or significant information, such as filing of applications, approvals, initiation of studies, and conclusions.
Want to be better informed than your competition? Get future stem cell industry updates.
BioInformant is the only research firm to serve the stem cell sector since it emerged. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, and Becton Dickinson, BioInformant is your global leader in stem cell industry data.
Click here to view our global strategic reports for the stem cell and cord blood industry.